To clarify the related mechanisms of astrocytic GluN2A which protect neurons against the early Aβ synaptotoxicity through regulating NGF could provide a pharmacological strategies aiming to increase an endogenous neuroprotective NGF level for early treatment of AD. This evidence concerns the gene GRIN2A and Alzheimer disease.